Achtnichts L - Search Results

1

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW. Kappos L, et al. Among authors: achtnichts l. J Neurol. 2004 Sep;251 Suppl 5:v57-v64. doi: 10.1007/s00415-004-1509-6. J Neurol. 2004. PMID: 15549357 Review.

2

Stroke-like presentation in a case of Creutzfeldt-Jakob disease.

Szabo K, Achtnichts L, Grips E, Binder J, Gerigk L, Hennerici M, Gass A. Szabo K, et al. Among authors: achtnichts l. Cerebrovasc Dis. 2004;18(3):251-3. doi: 10.1159/000080109. Epub 2004 Aug 6. Cerebrovasc Dis. 2004. PMID: 15305071 No abstract available.

3

Genomics and proteomics: role in the management of multiple sclerosis.

Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sandbrink R, Lindberg RL. Kappos L, et al. Among authors: achtnichts l. J Neurol. 2005 Sep;252 Suppl 3:iii21-iii27. doi: 10.1007/s00415-005-2013-3. J Neurol. 2005. PMID: 16170496 Review.

4

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.

Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Lindberg RL, et al. Among authors: achtnichts l. J Neuroimmunol. 2008 Feb;194(1-2):153-64. doi: 10.1016/j.jneuroim.2007.11.007. Epub 2008 Feb 21. J Neuroimmunol. 2008. PMID: 18178259

5

["Numb chin syndrome": first presenting syndrome of multiple sclerosis?].

Oestmann A, Achtnichts L, Kappos L, Gass A, Naegelin Y. Oestmann A, et al. Among authors: achtnichts l. Dtsch Med Wochenschr. 2008 Jan;133(3):76-8. doi: 10.1055/s-2008-1017477. Dtsch Med Wochenschr. 2008. PMID: 18186008 German.

6

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Yang M, Eraksoy M, Meluzinova E, Rektor I, Dawson KT, Sandrock AW, O'Neill GN; BG-12 Phase IIb Study Investigators. Kappos L, et al. Lancet. 2008 Oct 25;372(9648):1463-72. doi: 10.1016/S0140-6736(08)61619-0. Lancet. 2008. PMID: 18970976 Clinical Trial.

7

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group. O'Connor P, et al. Neurology. 2009 Jan 6;72(1):73-9. doi: 10.1212/01.wnl.0000338569.32367.3d. Neurology. 2009. PMID: 19122034 Clinical Trial.

8

SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.

Kamm CP, Mattle HP; SWABIMS Study Group. Kamm CP, et al. Trials. 2009 Dec 14;10:115. doi: 10.1186/1745-6215-10-115. Trials. 2009. PMID: 20003436 Free PMC article. Clinical Trial.

9

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group. Comi G, et al. Mult Scler. 2010 Feb;16(2):197-207. doi: 10.1177/1352458509357065. Epub 2009 Dec 22. Mult Scler. 2010. PMID: 20028707 Clinical Trial.

10

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Radue EW, et al. J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16. J Neurol Sci. 2010. PMID: 20236661 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters